Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisavanbulin in advanced solid tumors
NCT01397929Phase 2Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Jun 2011
- Primary completion
- Jan 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisavanbulin in colorectal cancer (CRC), gastric cancer (GC), gastroesophageal junction cancer, non-small cell lung cancer (NSCLC), ovarian cancer, sponsored by Basilea Pharmaceutica. Started Jun 2011; status: completed.
02
Drugs
lisavanbulin
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction cancernon-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT01397929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397929.